Navigation Links
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS)

s a disease modifying treatment for multiple sclerosis (MS). Active Biotech developed laquinimod and licensed it to Teva Pharmaceutical Industries, Ltd. in June 2004. A previous 24-week Phase IIa trial conducted by Active Biotech demonstrated that oral 0.3 mg laquinimod given daily was well tolerated and reduced the formation of active lesions in RRMS. To date, 460 MS patients have received laquinimod in various clinical trials.

About MS

Multiple Sclerosis (MS) is the leading cause of neurological disability in young adults. It is estimated that 400,000 people in the United States are affected by this disease, and that over one million people are affected worldwide. MS is a progressive, demyelinating disease of the central nervous system affecting the brain, spinal cord and optic nerves.

Patients with MS may experience physical symptoms and/or cognitive impairments, including weakness, fatigue, ataxia, physical dysfunction, bladder and bowel problems, sensory effects, and visual impairment. MS also has a significant impact on the sufferers' social functioning and overall quality of life.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

About Active Biotech

Active Biotech AB (ACTI.ST) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:2/27/2015)... 27, 2015  Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology, announced today that ... Officer, will present live at VirtualInvestorConferences.com on March ... join us for this Company update," said Mr. ... commercial launch of the exVive3D Liver, Bioprinted Human ...
(Date:2/27/2015)... JERUSALEM , Feb. 27, 2015  Chiasma, ... its lead product for the orphan condition acromegaly, today ... financing round. Participants in the financing included new investors ... blue chip public investment fund, as well as existing ... Abingworth and ARCH Venture Partners. Chiasma ...
(Date:2/26/2015)... -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), ... and t:flex™ Insulin Pumps, today announced the pricing of ... common stock at a price to the public of ... this offering are expected to be $56.3 million, after ... expenses payable by Tandem. All of the shares of ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
... announces that a new market research report is available ... Blood Banking Market http://www.reportlinker.com/p0365340/The-2011-Japanese-Blood-Banking-Market.html ... the Japanese blood banking market, including: Major ... well as key economic, regulatory, demographic, social and technological ...
... announces that a new market research report is ... of the Western European Peripheral Interventional Devices Market ... The objective of this research service is ... European peripheral interventional devices market. This service provides ...
Cached Medicine Technology:Reportlinker Adds The 2011 Japanese Blood Banking Market 2Reportlinker Adds Overview of the Western European Peripheral Interventional Devices Market 2
(Date:2/28/2015)... The World Scout League Commission (WSLC), ... potential EMTs and firefighters, recently announced its decision to ... to raise charitable donations for age-related research. The five-kilometer ... be held on March 29, 2015; registration will start ... 3:30 p.m. , To participate in the race, ...
(Date:2/27/2015)... Hispanics develop alcoholic liver disease (ALD), a ... years earlier than Whites/Caucasians or African Americans, according to ... While previous research indicated that Hispanics tend to have ... -- published online in the journal Alcoholism: Clinical and ... to pinpoint racial and ethnic disparities in the ages ...
(Date:2/27/2015)... Beverly Hills, CA (PRWEB) February 27, 2015 ... Health found a correlation between men who cycle on ... for your overall health, the study suggests that the more ... he is to develop prostate cancer, leading to an increased ... important because it allows physicians to look more closely at ...
(Date:2/27/2015)... 2015 Today, February 27th, is "Shine A ... along with LXR Organics and Living Fuel, ... to raise awareness and promote prevention, rescue and restoration for ... the END IT Coalition, slavery is the 2nd largest global ... in 167 countries around the world. Slavery includes bonded labor, ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Altec ... LLP (BPW) has been chosen as their doc-link for ... GP, CRM and other complimentary solutions for their customers ... working with credit unions. Altec and BPW have worked ... doc-link’s integration to Dynamics GP. , “We are so ...
Breaking Medicine News(10 mins):Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
... 2008, TORONTOWhen men present in emergency departments with pneumonia, ... have a greater risk of dying over the next ... according to research from the University of Pittsburgh that ... International Conference in Toronto on Tuesday, May 20. Even ...
... recurring disease, researchers say , , SUNDAY, May 18 ... cancer appears safe and may be effective, according to ... could give hope to men with metastatic prostate cancer ... The vaccine was developed to enable a patient,s immune ...
... children need food, water, shelter, BEIJING, May ... is rushing today to pack and ship emergency ... earthquake which devastated several,counties in central Sichuan. The ... being called the most powerful earthquake to hit ...
... PHILADELPHIA - A poster session presented today by The ... the Oncology Nurses Society 33rd Annual Congress, found that ... lead to a decrease in the incidence of lymphedema, ... life in breast cancer patients. , The literature ...
... In the aftermath of central China,s,earthquake, up ... their lives, and,over 150,000 were injured. An estimated ... who have lost their homes. With great sorrow ... Hai donated an,additional US$30,000, for a total of ...
... hormone readings, study says , , FRIDAY, May 16 (HealthDay News) ... a hormone secreted by the parathyroid glands may increase the ... report. , The Dutch study, published in the May ... speculation by researchers that vitamin D, depression and other psychiatric ...
Cached Medicine News:Health News:Gender disparity in community-acquired pneumonia 2Health News:Prostate Cancer Vaccine Looks Promising in Early Trial 2Health News:Prostate Cancer Vaccine Looks Promising in Early Trial 3Health News:Updated: UNICEF Rushing Emergency Relief to Children in Sichuan 2Health News:Updated: UNICEF Rushing Emergency Relief to Children in Sichuan 3Health News:M. D. Anderson nurse addresses lymphedema in breast cancer patients and survivors 2Health News:M. D. Anderson nurse addresses lymphedema in breast cancer patients and survivors 3Health News:Supreme Master Ching Hai International Association Delivering US$160,000 in Aid to Earthquake Survivors in China 2Health News:Low Vitamin D Tied to Depression in Older Adults 2
... Shandon Hyperclean 20 fume containment system ... with a swing-down front panel hinges ... the front opening. The sides ... acrylic which is impervious to most ...
... test delivers excellent sensitivity and specificity for ... simple, easy-to-use test that provides results in ... and ease-of-use enables you to deliver improved ... diagnosing and treating patients with pharyngitis. The ...
... The FLU OIA A/B test combines performance equivalence ... of Influenza A or B with a simple, ... minutes. The test has all the same procedural ... test will enable you decrease costs for unnecessary ...
... The Acceava Mononucleosis test provides superior ... with a simple procedure that provides ... evaluations with competitive products will convince ... attributes enable you to deliver improved ...
Medicine Products: